XBiotech Inc.
corporate_fare Company Profile
XBiotech Inc. (NASDAQ:XBIT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 3 items for XBIT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-06-15, rated 8/10. Across its 3 most recent items scored 7 or higher, the top rating is 9/10, with 3 rated 8 or above. Recent SEC coverage for XBIT spans 10-K/A, 10-K.
Recent high-impact activity:
- XBiotech's Vilamakitug Advances to Phase II for Spondyloarthritis After FDA Clearance
- XBiotech Discloses $30M Payout to Former CEO, Details New Equity Plan in Amended 10-K
- XBiotech Reports Mixed Clinical Trial Results: Positive Oncology Data, Failed Rheumatology Study, and Increased Annual Loss
Financial Snapshot
Short Interest & Short Volume
4.97 days to coverFINRA reported short interest of 347,119 shares in XBIT as of the September 15, 2026 settlement, a 1.3% increase from the prior period — about 5.0 days to cover at its recent average daily volume. On October 2, 2026, 3.5% of XBIT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.